SEREVENT DISKUS Rx
Generic Name and Formulations:
Salmeterol (as xinafoate) 50mcg/inh; dry pwd for inhalation; device with drug in blisters.
Indications for SEREVENT DISKUS:
As an adjunct (see full labeling): For the maintenance treatment of asthma and in the prevention of bronchospasm in reversible obstructive airway disease (including nocturnal asthma). Maintenance treatment of COPD-associated bronchospasm. Prevention of exercise-induced bronchospasm (EIB).
Adults and Children:
<4yrs: not recommended. ≥4yrs: 1 inh every 12 hours. EIB prevention: 1 inh at least 30 minutes before exercise. Max 2 doses/day. Do not use additional doses for EIB if already using regular dosing for asthma. COPD-associated bronchospasm: 1 inh every 12 hours.
For asthma: without concomitant use of a long-term asthma control drug (eg, inhaled corticosteroid). Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures. Allergy to milk proteins.
Increased risk of asthma-related deaths and hospitalizations. Prescribe for asthma only as additional therapy with an inhaled corticosteroid. Do not initiate in rapidly or acutely deteriorating asthma or COPD. Not for relief of acute bronchospasm. Salmeterol is not a substitute for steroids. Not for use with other long-acting β2-agonists. Do not exceed recommended dose. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Hepatic impairment (monitor). Evaluate response before altering steroid doses. Prescribe an additional short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Long-acting beta-2 agonist (LABA).
Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, atazanavir, clarithromycin, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin): not recommended. Caution during or within 2 weeks of MAOIs or tricyclic antidepressants (increased cardiovascular effects). Antagonized by β-blockers. Caution with K+-depleting diuretics.
Headache, influenza, nasal/sinus congestion, pharyngitis, rhinitis, tracheitis/bronchitis, cough, musculoskeletal pain, throat irritation, viral respiratory infection; paradoxical bronchospasm (discontinue if occurs); rarely: serious asthma episode, asthma-related death.
Diskus (w. 60 blisters)—1
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years